Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acipimox for nonalcoholic fatty liver disease with abnormal ALT
ChiCTR-IPR-17012342Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Southwest Medical University
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of acipimox in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Affiliated Hospital of Southwest Medical University. Primary endpoints: height, weight and 12 more. Planned start Aug 2017; status: not yet recruiting.
02
Drugs
acipimox
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR-IPR-17012342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012342.